Seminars in Hematology
Volume 40, Issue 4 , Pages 296-307 , October 2003

Towards molecular diagnosis and targeted therapy of lymphoid malignancies

  • Adrian Wiestner

      Affiliations

    • Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Bethesda, MD, USA
    • Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    • ,
  • Louis M Staudt

      Affiliations

    • Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Bethesda, MD, USA
    • Corresponding Author InformationAddress correspondence to Louis M. Staudt, MD, PhD, Metabolism Branch, CCR, NCI, Bldg 10, Room 4N114, NIH, Bethesda, MD 20892, USA

References 

  1. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol. 2002;6:493–500
  2. Aisenberg AC. Historical review of lymphomas. Br J Haematol. 2000;109:466–476
  3. Alizadeh AA, Eisen MB, Davis RE, et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  4. Argatoff LH, Connors JM, Klasa RJ, et al.  Mantle cell lymphoma (A clinicopathologic study of 80 cases). Blood. 1997;89:2067–2078
  5. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–246
  6. Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol. 2001;2:141–148
  7. Bea S, Tort F, Pinyol M, et al.  BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61:2409–2412
  8. Borche L, Lim A, Binet JL, et al.  Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood. 1990;76:562–569
  9. Bosch F, Lopez-Guillermo A, Campo E, et al.  Mantle cell lymphoma (Presenting features, response to therapy, and prognostic factors). Cancer. 1998;82:567–575
  10. Caligaris-Cappio F. B-chronic lymphocytic leukemia (A malignancy of anti-self B cells). Blood. 1996;87:2615–2620
  11. Chen L, Widhopf G, Huynh L, et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609–4614
  12. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia (Lessons Learned from studies of the B cell antigen receptor). Annu Rev Immunol. 2003;21:841–894
  13. Coiffier B, Lepage E, Briere J, et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  14. Crespo M, Bosch F, Villamor N, et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775
  15. Damle RN, Wasil T, Fais F, et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  16. Damle RN, Ghiotto F, Valetto A, et al.  B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087–4093
  17. Davis RE, Brown KD, Siebenlist U, et al.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–1874
  18. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, et al.  Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene. 1995;10:1833–1840
  19. Dreyling MH, Bullinger L, Ott G, et al.  Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res. 1997;57:4608–4614
  20. Dyer MJ, Oscier DG. The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia. 2002;16:973–984
  21. Eisen MB, Spellman PT, Brown PO, et al.  Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868
  22. Falini B, Fizzotti M, Pucciarini A, et al.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084–2092
  23. Fisher RI, Gaynor ER, Dahlberg S, et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  24. Gascoyne RD, Adomat SA, Krajewski S, et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–251
  25. Gianni AM, Magni M, Martelli M, et al.  Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749–755
  26. Gopal AK, Rajendran JG, Petersdorf SH, et al.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158–3162
  27. Greiner TC, Moynihan MJ, Chan WC, et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302–4310
  28. Grogan TM, Lippman SM, Spier CM, et al.  Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988;71:1157–1160
  29. Hamblin TJ, Davis Z, Gardiner A, et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  30. Hernandez L, Fest T, Cazorla M, et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351–3359
  31. Howard OM, Gribben JG, Neuberg DS, et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma (Molecular complete responses are not predictive of progression-free survival). J Clin Oncol. 2002;20:1288–1294
  32. Huang JZ, Sanger WG, Greiner TC, et al.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285–2290
  33. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al.  Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4:321–329
  34. Jaffe ES, Harris NL, Stein H, et al.  Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001;
  35. Khouri IF, Romaguera J, Kantarjian H, et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation (An active regimen for aggressive mantle-cell lymphoma). J Clin Oncol. 1998;16:3803–3809
  36. Khouri IF, Lee MS, Romaguera J, et al.  Allogeneic hematopoietic transplantation for mantle-cell lymphoma (Molecular remissions and evidence of graft-versus-malignancy). Ann Oncol. 1999;10:1293–1299
  37. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993;81:2475–2487
  38. Klein U, Tu Y, Stolovitzky GA, et al.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625–1638
  39. Krober A, Seiler T, Benner A, et al.  VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416
  40. Lanham S, Hamblin T, Oscier D, et al.  Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087–1093
  41. Lardelli P, Bookman MA, Sundeen J, et al.  Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol. 1990;14:752–763
  42. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al.  A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene. 1994;9:1925–1929
  43. Lin S, Wang W, Wilson GM, et al.  Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol. 2000;20:7903–7913
  44. List AF, Spier CM, Miller TP, et al.  Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma (Relationship to HLA expression and host immunocompetence). Leukemia. 1993;7:398–403
  45. Lossos IS, Alizadeh AA, Eisen MB, et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA. 2000;97:10209–10213
  46. Louie DC, Offit K, Jaslow R, et al.  p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 1995;86:2892–2899
  47. Orchard J, Ibbotson R, Davis Z, et al: ZAP-70 expression by flow cytometry: A new prognostic marker in CLL. Lancet (in press)
  48. Oscier DG, Gardiner AC, Mould SJ, et al.  Multivariate analysis of prognostic factors in CLL (clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors). Blood. 2002;100:1177–1184
  49. Pinyol M, Cobo F, Bea S, et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood. 1998;91:2977–2984
  50. Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259–263
  51. Raty R, Franssila K, Joensuu H, et al.  Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002;69:11–20
  52. Reimold AM, Iwakoshi NN, Manis J, et al.  Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412:300–307
  53. Rimokh R, Berger F, Bastard C, et al.  Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994;83:3689–3696
  54. Rosenberg CL, Wong E, Petty EM, et al.  PRAD1, a candidate BCL1 oncogene (Mapping and expression in centrocytic lymphoma). Proc Natl Acad Sci USA. 1991;88:9638–9642
  55. Rosenwald A, Alizadeh AA, Widhopf G, et al.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1648
  56. Rosenwald A, Wright G, Chan WC, et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  57. Rosenwald A, Wright G, Wiestner A, et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185–197
  58. Schweighoffer E, Vanes L, Mathiot A, et al.  Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity. 2003;18:523–533
  59. Seto M, Yamamoto K, Iida S, et al.  Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene. 1992;7:1401–1406
  60. Shaffer AL, Rosenwald A, Hurt EM, et al.  Signatures of the immune response. Immunity. 2001;15:375–385
  61. Shaffer AL, Lin KI, Kuo TC, et al.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51–62
  62. Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187–190
  63. Sherr CJ, Roberts JM. CDK inhibitors (Positive and negative regulators of G1-phase progression). Genes Dev. 1999;13:1501–1512
  64. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–112
  65. Shipp MA, Ross KN, Tamayo P, et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74
  66. Silvestrini R, Costa A, Boracchi P, et al.  Cell proliferation as a long-term prognostic factor in diffuse large- cell lymphomas. Int J Cancer. 1993;54:231–236
  67. Staudt LM, Brown PO. enomic views of the immune system. GAnn Rev Immunol. 2000;18:829–859
  68. Staudt LM. Molecular diagnosis of the hematological cancers. N Engl J Med. 2003;348:1777–1785
  69. Stopeck AT, Gessner A, Miller TP, et al.  Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res. 2000;6:3904–3909
  70. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma (A clinicopathologic and molecular review of 3 decades). Hum Pathol. 2002;33:7–20
  71. The Non-Hodgkin’s Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–3918
  72. Tobin G, Thunberg U, Johnson A, et al.  Somatically mutated Ig VH3–21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262–2264
  73. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al.  Mantle-cell lymphoma (A population-based clinical study). J Clin Oncol. 1996;14:1269–1274
  74. Vose JM, Bierman PJ, Weisenburger DD, et al.  Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2000;6:640–645
  75. Weller S, Faili A, Garcia C, et al.  CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA. 2001;98:1166–1170
  76. Wiestner A, Rosenwald A, Barry TS, et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes inferior clinical outcome and distinct gene expression profile. Blood. 2003;101:4944–4951
  77. William J, Euler C, Christensen S, et al.  Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science. 2002;297:2066–2070
  78. Wilson WH, Grossbard ML, Pittaluga S, et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas (A pharmacodynamic approach with high efficacy). Blood. 2002;99:2685–2693
  79. Withers DA, Harvey RC, Faust JB, et al.  Characterization of a candidate bcl-1 gene. Mol Cell Biol. 1991;11:4846–4853
  80. Wright G, Tan B, Rosenwald A, et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B Cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–9996

PII: S0037-1963(03)00194-X

doi: 10.1016/S0037-1963(03)00194-X

Seminars in Hematology
Volume 40, Issue 4 , Pages 296-307 , October 2003

Article Tools

* Image Usage & Resolution